Safety study of two asthma inhaler propellants over 4 weeks
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial compares the safety of two different propellants (the gases that push medicine out of inhalers) in people with well-controlled asthma. Researchers want to ensure both propellants are safe to use in asthma inhalers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have had asthma diagnosed for at least 6 months and be on a stable asthma treatment for at least 12 weeks
- Have good lung function (at least 50% of predicted) and well-controlled asthma with an ACQ-6 score below 1.5
- Have not had a severe asthma attack in the last 3 months
- Be a non-smoker (no cigarettes, vaping, or marijuana inhaled in the last 12 months) with 10 pack-years or fewer smoking history
- Be able to use a pressurized metered-dose inhaler (pMDI) device correctly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two versions of the common asthma rescue inhaler (salbutamol/albuterol) that use different propellants (the gas that pushes the medicine out). The goal is to see if the new propellant works as well as the current one. If you have mild asthma and are on a stable treatment plan, you may be able to join.
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
This trial tests whether a new inhaler (CHF5993) works as well as the current standard for adults with mild to moderate asthma. It compares how well the medicine controls asthma and opens airways.
This study tests a new combination inhaler (fluticasone propionate and albuterol) for people with asthma age 12 and older. It helps see if this inhaler works better than a placebo in controlling asthma symptoms and preventing attacks.
This study tests a new three-part asthma inhaler (CHF 5993) in people whose asthma isn't well-controlled even though they're already using two standard asthma medicines together. The goal is to see if adding this new medicine helps control asthma better.
This Phase 2 study checks how glycopyrronium bromide works in children with asthma, including its safety and how well inhaler dosing is tolerated. It also uses breathing tests and inhaler technique checks to confirm your child meets key asthma and lung function requirements.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.